ALPHARX TO ACCELERATE INDAFLEX TRIAL

AlphaRx has announced the addition of three new sites for its Phase II multicenter clinical trial of Indaflex, a topical Indomethacin drug expected to treat patients suffering from osteoarthritis of the knee. The company believes that the three new sites, in addition to the existing 10 sites, will accelerate patient enrollment toward the targeted completion date of February 2006.

Indaflex is a topical NSAID (nonsteroidal anti-inflammatory drug) formulation under clinical development for the treatment of arthritis symptoms. Osteoarthritis is the most common chronic disease in North America and afflicts an estimated 10 percent of the world's population. Indaflex's active ingredient, Indomethacin, has a long-standing and proven clinical treatment record. Topical Indaflex delivery may circumvent the significant gastrointestinal side-effects commonly found with orally ingested NSAIDs.